SCHEMBL3175328

SCHEMBL3175328

Nc1ccc2c(c1N)Sc1ccccc1S2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 7/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 3/20 0.38
BCHE P06276 3/20 0.38
ACHE P22303 3/20 0.38
MAOA P21397 3/20 0.38
SLC6A2 P23975 2/20 0.38
HTR2C P28335 2/20 0.38
CYP3A4 P08684 2/20 0.38
ALOX15 P16050 2/20 0.38
GAA P10253 2/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ALOX12 P18054 1/20 0.38
CNR1 P21554 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
SNCA P37840 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9479473 0.89
SCHEMBL15089121 0.77 PTPN5 (0.47) NOX1MEN1KMT2AMAPTBCHE
SCHEMBL30994886 0.74 CYP3A4 (0.35) NOX1MEN1KMT2AMAPTBCHE
SCHEMBL28405771 0.72 MEN1 (0.41) NOX1MEN1KMT2AMAPTSLC6A2
SCHEMBL22561858 0.70 MEN1 (0.55) NOX1MEN1KMT2AMAPTBCHE
SCHEMBL30823 0.69
Thianthrene SCHEMBL7786 0.69 BCHE (0.56) NOX1MEN1KMT2AMAPTBCHE
SCHEMBL21629348 0.69 BCHE (0.56) NOX1MEN1KMT2AMAPTBCHE
Thianthrene SCHEMBL29392368 0.69 BCHE (0.56) NOX1MEN1KMT2AMAPTBCHE
SCHEMBL25643861 0.69 BCHE (0.56) NOX1MEN1KMT2AMAPTBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7658868-B2 Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-02-09 US disclosed
US-20070215839-A1 Molecular actuators, and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-09-20 US disclosed
US-7138075-B2 Molecular actuators, and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2006-11-21 US disclosed
US-20040007695-A1 Molecular actuators, and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070215839-A1 Molecular actuators, and methods of use thereof NOD2, PIEZO1, TPR NOX1 3248/4885MEN1 4570/4885KMT2A 4720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.